Louise Ramos
Doctor of Philosophy in Experimental Medicine (PhD)
Research Topic
Characterization of a novel bifunctional PARP-HDAC inhibitor in a 3-D printed human-mimetic bone model
Nada Lallous
Assistant Professor
Research Classification
Research Interests
Biochemistry
Biophysics
Cancer biology
Therapeutics
Protein research
Drug resistance
transcription factors
Relevant Thesis-Based Degree Programs
Research Options
I am available and interested in collaborations (e.g. clusters, grants).
I am interested in and conduct interdisciplinary research.
I am interested in working with undergraduate students on research projects.
Research Methodology
Isothermal Titration Calorimetry (ITC)
MicroScale Thermophoresis (MST)
Meso Scale discovery (MSD)
BioLayer Interferometry (BLI)
Fluorescence-based assays
Dynamic light scattering (DLS)
Fast protein liquid chromatography (FPLC)
Recruitment
Master's students
2021
Expression, purification and biophysical characterization of various prostate cancer targets.
Complete these steps before you reach out to a faculty member!
Check requirements
- Familiarize yourself with program requirements. You want to learn as much as possible from the information available to you before you reach out to a faculty member. Be sure to visit the graduate degree program listing and program-specific websites.
- Check whether the program requires you to seek commitment from a supervisor prior to submitting an application. For some programs this is an essential step while others match successful applicants with faculty members within the first year of study. This is either indicated in the program profile under "Admission Information & Requirements" - "Prepare Application" - "Supervision" or on the program website.
Focus your search
- Identify specific faculty members who are conducting research in your specific area of interest.
- Establish that your research interests align with the faculty member’s research interests.
- Read up on the faculty members in the program and the research being conducted in the department.
- Familiarize yourself with their work, read their recent publications and past theses/dissertations that they supervised. Be certain that their research is indeed what you are hoping to study.
Make a good impression
- Compose an error-free and grammatically correct email addressed to your specifically targeted faculty member, and remember to use their correct titles.
- Do not send non-specific, mass emails to everyone in the department hoping for a match.
- Address the faculty members by name. Your contact should be genuine rather than generic.
- Include a brief outline of your academic background, why you are interested in working with the faculty member, and what experience you could bring to the department. The supervision enquiry form guides you with targeted questions. Ensure to craft compelling answers to these questions.
- Highlight your achievements and why you are a top student. Faculty members receive dozens of requests from prospective students and you may have less than 30 seconds to pique someone’s interest.
- Demonstrate that you are familiar with their research:
- Convey the specific ways you are a good fit for the program.
- Convey the specific ways the program/lab/faculty member is a good fit for the research you are interested in/already conducting.
- Be enthusiastic, but don’t overdo it.
Attend an information session
G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.
ADVICE AND INSIGHTS FROM UBC FACULTY ON REACHING OUT TO SUPERVISORS
These videos contain some general advice from faculty across UBC on finding and reaching out to a potential thesis supervisor.
Supervision Enquiry
If you have reviewed some of this faculty member's publications, understand their research interests and have reviewed the admission requirements, you may submit a contact request to this supervisor.
Publications
- Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer (2022)
International Journal of Molecular Sciences, - Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors (2022)
Cells, - Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer (2021)
Cancers, - Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor (2021)
International Journal of Molecular Sciences, - Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients (2021)
Cancers, - Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy (2021)
Cancers, - Androgen receptor-binding sites are highly mutated in prostate cancer (2020)
Nature Communications, 11 (1) - Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies (2020)
International Journal of Molecular Sciences, - Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer (2020)
International Journal of Molecular Sciences, - Androgen receptor plasticity and its implications for prostate cancer therapy (2019)
Cancer Treatment Reviews, 81, 101871 - Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer (2019)
Molecules, 24 (4), 763 - Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models (2019)
Journal of Clinical Investigation, 130 (2), 699--714 - Targeting HP1-alpha for prevention and treatment of neuroendocrine prostate cancer (2019)
Oncology Abstracts, - 20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors (2018)
Oncotarget, 9 (30), 20965--20978 - Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers (2018)
International Journal of Molecular Sciences, - Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer (2018)
European Journal of Medicinal Chemistry, 160, 108--119 - Head-to-head comparison of efficacy of darolutamide (ODM-201) vs. enzalutamide on mutated forms of the androgen receptor (2018)
European Urology Supplements, 17 (2), e505 - Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201) (2018)
European Urology, 73 (1), 4--8 - An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer (2017)
European Urology, 72 (1), 142--150 - Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions (2017)
Molecular Cancer Therapeutics, 16 (10), 2281--2291 - Abstract 4644: Inhibition of the androgen receptor at two drug-targetable sites on the DNA-binding domain protein surface (2016)
Experimental and Molecular Therapeutics, - Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor (2016)
Journal of Chemical Information and Modeling, 56 (12), 2507--2516 - Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor (2016)
Methods in Molecular Biology, , 31--54 - Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients (2016)
Genome Biology, 17 (1) - Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation (2016)
Molecular Cancer Therapeutics, 15 (12), 2936--2945 - Abstract 3653: Structure-based study to overcome cross-reactivity of novel androgen receptor inhibitors (2015)
Cancer Chemistry, - In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α (2015)
Breast Cancer Research, 17 (1) - Structure-based study to overcome cross-reactivity of novel androgen receptor inhibitors (2015)
- Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 5.5 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 6.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 6.5 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 7.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 7.5 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 8.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to the inhibitor fluoroorotate at pH 6.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD bound to the inhibitor fluoroorotate at pH 7.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD C1613S mutant bound to substrate at pH 7.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD C1613S mutant in apo-form at pH 6.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD C1613S mutant in apo-form at pH 7.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD E1637T mutant bound to substrate at pH 6.0 (2014)
- Crystal structure of the dihydroorotase domain of human CAD in apo- form obtained recombinantly from E. coli. (2014)
- Crystal structure of the dihydroorotase domain of human CAD in apo- form obtained recombinantly from HEK293 cells. (2014)
- Crystal structure of the dihydroorotase domain of human CAD with incomplete active site, obtained recombinantly from E. coli. (2014)
- Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer (2014)
Chemistry & Biology, 21 (11), 1476--1485 - Structure, Functional Characterization, and Evolution of the Dihydroorotase Domain of Human CAD (2014)
Structure, 22 (2), 185--198 - Expression, purification, crystallization and preliminary X-ray diffraction analysis of the aspartate transcarbamoylase domain of human CAD (2013)
Acta Crystallographica Section F Structural Biology and Crystallization Communications, 69 (12), 1425--1430 - Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer (2013)
International Journal of Molecular Sciences, 14 (6), 12496--12519 - Expression, purification, crystallization and preliminary X-ray diffraction analysis of the dihydroorotase domain of human CAD (2012)
Acta Crystallographica Section F Structural Biology and Crystallization Communications, 68 (11), 1341--1345 - Chromatin Recognition Protein Modules: The PHD Finger (2011)
Encyclopedia of Life Sciences, - PHD finger of human UHRF1 (2011)
- PHD finger of human UHRF1 in complex with unmodified histone H3 N- terminal tail (2011)
- The PHD Finger of Human UHRF1 Reveals a New Subgroup of Unmethylated Histone H3 Tail Readers (2011)
PLoS ONE, 6 (11), e27599 - Expression, purification, crystallization and preliminary crystallographic study of the SRA domain of the human UHRF1 protein (2008)
Acta Crystallographica Section F Structural Biology and Crystallization Communications, 64 (10), 922--925
Current Students & Alumni
This is a small sample of students and/or alumni that have been supervised by this researcher. It is not meant as a comprehensive list.
Membership Status
Partner appointment
View explanation of statuses
Location
Vancouver General Hospital
Program Affiliations
Academic Unit(s)
If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.
